(Reuters) – The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals’ drug-device combination to treat movement-related symptoms of Parkinson’s disease, the drugmaker said on Tuesday. The treatment branded Onapgo will be available in the U.S. in the second quarter. The drug regulator’s greenlight brings an end in the company’s years-long effort to market the pump-based